


BIOTECHNOLOGY & PHARMACEUTICAL



HATCH-WAXMAN

Brinks conducts validity and infringement reviews in connection with Paragraph IV certifications for abbreviated new drug applications or 505(b)(2) applications, and represents clients in related Hatch-Waxman litigation and other litigation in this and related fields. A representative list of compounds that we have worked on is below.

Generic Product	Branded Product	Generic Product	Branded Product
Alcaftadine	Lastacaft®	Methylphenidate osmotic release	Concerta®
Besifloxacin	Besivance®	Methylphenidate transdermal patch	Daytrana®
Bimatoprost	Lumigan®	Montelukast sodium	Singulair®
Budesonide	Symbicort®	Omeprazole	Prilosec®
Bupropion	Wellbutrin XL®	Pantoprazole	Protonix®
Caspofungin	Cancidas®	Paroxetine mesylate capsules	Brisdelle(R)
Choline fenofibric acid	Trilipix®	Polycarbophil/chitosan ophthalmic	DuraSite 2®
Cefdinir	Omnicef®	Pramipexole	Miramax ER®
Diclofenac sodium	Diclofenac sodium	Pregabalin	Lyrica®
Dorzolamide-timolol	Cosopt PF®	Repaglinide/metformin	PrandiMet®
Doxercalciferol	Hectorol®	Ropivacaine hydrochloride monohydrate	Naropin®
Duloxetine	Cymbalta®	Rosuvastatin calcium	Crestor®
Enoxaparin sodium	Lovenox®	Saxagliptin	Onglyza(R)
Eptifibatide	Integrilin®	Saxagliptin/metformin extended release	
Esomeprazole	Nexium®	Sevelamer hydrochloride	Renagel®
Festerodine	Toviaz®	Valganciclovir hydrochloride	Valcyte®
Febuxostat	Uloric®	Valganciclovir	Valcyte(R) oral solution
Galantamine hydrobromide	Razadyne ER®	Venlafaxine	Effexor®
Gemcitabine	Gemzar®	Zolpidem	Ambien®
Levocetirizine	Xyzal®		
Memantine	Namenda XR®		